Meglumine
Dibasic, Monobasic, Monohydrate, Phosphate (meglumine) is a small molecule pharmaceutical. Meglumine was first approved as Sodium phosphates in plastic container on 1983-05-10. It is used to treat aids-related opportunistic infections, cutaneous leishmaniasis, and visceral leishmaniasis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Calcium
+
Meglumine
+
Metrizoic acid
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ISOPAQUE 280 | GE Healthcare | N-017506 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| baxdela | New Drug Application | 2021-07-02 |
| clariscan | ANDA | 2025-05-19 |
| conray | New Drug Application | 2023-05-11 |
| cysto-conray | New Drug Application | 2010-07-08 |
| cysto-conray ii | New Drug Application | 2020-12-31 |
| cystografin | New Drug Application | 2018-04-15 |
| cystografin dilute | New Drug Application | 2018-10-02 |
| diatrizoate meglumine and diatrizoate sodium | ANDA | 2025-02-19 |
| dotarem | New Drug Application | 2025-03-14 |
| gadoterate meglumine | ANDA | 2025-04-16 |
Show 7 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cutaneous leishmaniasis | — | D016773 | B55.1 |
| visceral leishmaniasis | — | D007898 | B55.0 |
| aids-related opportunistic infections | — | D017088 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sodium Phosphate, Dibasic, Anhydrous / Sodium Phosphate, Monobasic, Monohydrate, Osmoprep, Salix Pharms | |||
| 7687075 | 2028-06-22 | DS, DP | |
Clinical
Clinical Trials
119 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leishmaniasis | D007896 | EFO_0005044 | B55 | 3 | 16 | 16 | 4 | 3 | 35 |
| Cutaneous leishmaniasis | D016773 | — | B55.1 | 3 | 14 | 14 | 2 | 3 | 30 |
| Healthy volunteers/patients | — | — | — | 11 | — | — | 1 | — | 12 |
| Ischemic stroke | D000083242 | — | — | — | 4 | 3 | 2 | 2 | 8 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 4 | 3 | 1 | 2 | 7 |
| Ischemia | D007511 | EFO_0000556 | — | — | 4 | 3 | 1 | 2 | 7 |
| Cerebral infarction | D002544 | — | I63 | — | 3 | 2 | 1 | 2 | 6 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | — | — | 1 | 3 | 1 | 5 |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | — | 1 | 3 | — | 4 |
| Amyloid neuropathies | D017772 | — | — | — | — | 1 | 3 | — | 4 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | 2 | — | 2 | 4 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | 2 | — | 2 | 4 |
| Mucocutaneous leishmaniasis | D007897 | EFO_0007379 | B55.2 | — | 2 | 2 | — | — | 3 |
| Central nervous system diseases | D002493 | — | G96.9 | — | — | 2 | — | — | 2 |
| Nervous system diseases | D009422 | — | G00-G99 | — | — | 1 | — | 1 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | 1 | 2 |
| Cerebral arterial diseases | D002539 | EFO_1000859 | — | — | — | 2 | — | — | 2 |
| Familial amyloid neuropathies | D028227 | — | E85.1 | — | — | 1 | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | 1 | — | — | 1 |
| Self-assessment | D012647 | — | — | — | — | 1 | — | — | 1 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | 1 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | — | — | 1 | 2 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | 1 | 1 | — | — | — | 2 |
| Local anesthesia | D000772 | — | — | 1 | 1 | — | — | — | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | 1 | — | — | — | 1 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | 1 | — | — | — | 1 |
| Magnetic resonance angiography | D018810 | — | — | — | 1 | — | — | — | 1 |
| Postoperative pain | D010149 | — | G89.18 | — | 1 | — | — | — | 1 |
| Acidosis | D000138 | EFO_1000014 | E87.2 | — | 1 | — | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 2 | — | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | 1 | 2 |
| Infarction | D007238 | EFO_0009463 | — | 1 | — | — | — | 1 | 2 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Fibroadenoma | D018226 | — | — | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | — | 1 |
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | 1 | — | — | — | — | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | — | — | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | — | — | — | 2 | 2 |
| Glioma | D005910 | EFO_0000520 | — | — | — | — | — | 2 | 2 |
| Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | — | — | — | — | 1 | 1 |
| Male breast neoplasms | D018567 | — | — | — | — | — | — | 1 | 1 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 1 | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 1 | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | — | 1 | 1 |
| Medulloblastoma | D008527 | — | — | — | — | — | — | 1 | 1 |
| Gliosarcoma | D018316 | — | — | — | — | — | — | 1 | 1 |
| Solitary fibrous tumors | D054364 | — | — | — | — | — | — | 1 | 1 |
Show 39 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Meglumine |
| INN | meglumine |
| Description | N-methylglucamine is a hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis. It is a hexosamine and a secondary amino compound. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO |
Identifiers
| PDB | — |
| CAS-ID | 6284-40-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200570 |
| ChEBI ID | 59732 |
| PubChem CID | 8567 |
| DrugBank | — |
| UNII ID | 6HG8UB2MUY (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Baxdela – Melinta Therapeutics /new/
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,853 documents
View more details
Safety
Black-box Warning
Black-box warning for: Baxdela, Clariscan, Conray, Cysto-conray, Cysto-conray ii, Dotarem, Gadoterate meglumine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,248 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use